Transgene SA Cash Flow Conversion Efficiency
Transgene SA cash flow conversion efficiency. Based on the latest financial reports, Transgene SA (TNG) has a cash flow conversion efficiency ratio of -0.152x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-18.55 Million ≈ $-21.69 Million USD) by net assets (€121.73 Million ≈ $142.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Transgene SA (1997–2025)
Cash flow conversion efficiency of Transgene SA from 1997 to 2025. This chart illustrates how Transgene SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Transgene SA for real-time trading data and today's change.
Transgene SA Cash Flow Conversion Ratio Explained
Transgene SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Transgene SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transgene SA ranked by their cash flow conversion efficiency. Also see TNG company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Iljin HySolus Co Ltd
KO:271940
|
0.006x |
|
Infinity Natural Resources, Inc.
NYSE:INR
|
-0.084x |
|
GSR IV Acquisition Corp. Class A ordinary share
NASDAQ:GSRF
|
-0.001x |
|
Santhera Pharmaceuticals Holding AG
SW:SANN
|
1.199x |
|
Banvit Bandirma Vitaminli Yem Sanayi AS
IS:BANVT
|
-0.067x |
|
BROOGE ENERGY DL-0001
F:3SF
|
N/A |
|
Rossari Biotech Limited
NSE:ROSSARI
|
0.024x |
|
Steppe Gold Ltd
TO:STGO
|
0.135x |
Annual Cash Flow Conversion Efficiency for Transgene SA (1997–2025)
The table below shows the annual cash flow conversion efficiency of Transgene SA from 1997 to 2025. Review how financially flexible is Transgene SA to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €121.73 Million ≈ $142.32 Million |
€-36.74 Million ≈ $-42.95 Million |
-0.302x | +80.52% |
| 2024-12-31 | €15.20 Million ≈ $17.78 Million |
€-23.55 Million ≈ $-27.53 Million |
-1.549x | +30.26% |
| 2023-12-31 | €15.61 Million ≈ $18.25 Million |
€-34.67 Million ≈ $-40.53 Million |
-2.221x | -313.91% |
| 2022-12-31 | €37.84 Million ≈ $44.24 Million |
€-20.30 Million ≈ $-23.74 Million |
-0.537x | -12.89% |
| 2021-12-31 | €67.21 Million ≈ $78.57 Million |
€-31.94 Million ≈ $-37.34 Million |
-0.475x | +16.91% |
| 2020-12-31 | €50.25 Million ≈ $58.75 Million |
€-28.74 Million ≈ $-33.60 Million |
-0.572x | -67.66% |
| 2019-12-31 | €65.70 Million ≈ $76.81 Million |
€-22.41 Million ≈ $-26.20 Million |
-0.341x | +55.88% |
| 2018-12-31 | €36.70 Million ≈ $42.91 Million |
€-28.38 Million ≈ $-33.18 Million |
-0.773x | +38.59% |
| 2017-12-31 | €28.09 Million ≈ $32.84 Million |
€-35.37 Million ≈ $-41.35 Million |
-1.259x | -74.35% |
| 2016-12-31 | €46.50 Million ≈ $54.37 Million |
€-33.59 Million ≈ $-39.26 Million |
-0.722x | +57.54% |
| 2015-12-31 | €26.55 Million ≈ $31.04 Million |
€-45.15 Million ≈ $-52.79 Million |
-1.701x | -125.29% |
| 2014-12-31 | €71.84 Million ≈ $83.99 Million |
€-54.24 Million ≈ $-63.41 Million |
-0.755x | +14.82% |
| 2013-12-31 | €56.62 Million ≈ $66.20 Million |
€-50.19 Million ≈ $-58.67 Million |
-0.886x | -72.06% |
| 2012-12-31 | €99.58 Million ≈ $116.42 Million |
€-51.29 Million ≈ $-59.97 Million |
-0.515x | -64.95% |
| 2011-12-31 | €141.42 Million ≈ $165.33 Million |
€-44.16 Million ≈ $-51.63 Million |
-0.312x | -130.02% |
| 2010-12-31 | €183.62 Million ≈ $214.67 Million |
€-24.93 Million ≈ $-29.14 Million |
-0.136x | +50.28% |
| 2009-12-31 | €68.56 Million ≈ $80.16 Million |
€-18.72 Million ≈ $-21.89 Million |
-0.273x | -10.00% |
| 2008-12-31 | €94.22 Million ≈ $110.16 Million |
€-23.39 Million ≈ $-27.34 Million |
-0.248x | -1228.28% |
| 2007-12-31 | €110.94 Million ≈ $129.70 Million |
€-2.07 Million ≈ $-2.42 Million |
-0.019x | +98.18% |
| 2006-12-31 | €18.98 Million ≈ $22.19 Million |
€-19.54 Million ≈ $-22.84 Million |
-1.029x | +23.32% |
| 2004-12-31 | €14.23 Million ≈ $16.64 Million |
€-19.11 Million ≈ $-22.34 Million |
-1.343x | -154.45% |
| 2003-12-31 | €34.52 Million ≈ $40.36 Million |
€-18.21 Million ≈ $-21.29 Million |
-0.528x | -81.78% |
| 2002-12-31 | €55.21 Million ≈ $64.54 Million |
€-16.02 Million ≈ $-18.73 Million |
-0.290x | -35.93% |
| 2001-12-31 | €73.63 Million ≈ $86.08 Million |
€-15.72 Million ≈ $-18.38 Million |
-0.214x | +66.64% |
| 2000-12-31 | €34.79 Million ≈ $40.67 Million |
€-22.27 Million ≈ $-26.03 Million |
-0.640x | -155.78% |
| 1999-12-31 | €55.48 Million ≈ $64.86 Million |
€-13.88 Million ≈ $-16.23 Million |
-0.250x | +45.04% |
| 1998-12-31 | €73.49 Million ≈ $85.92 Million |
€-33.47 Million ≈ $-39.13 Million |
-0.455x | +19.95% |
| 1997-12-31 | €20.68 Million ≈ $24.18 Million |
€-11.77 Million ≈ $-13.76 Million |
-0.569x | -- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) posi… Read more